Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients

Pharmacogenomics. 2021 Apr;22(5):263-274. doi: 10.2217/pgs-2020-0112. Epub 2021 Mar 4.

Abstract

Aim: To assess providers' knowledge, attitudes, perceptions, and experiences related to pharmacogenomic (PGx) testing in pediatric patients. Materials & methods: An electronic survey was sent to multidisciplinary healthcare providers at a pediatric hospital. Results: Of 261 respondents, 71.3% were slightly or not at all familiar with PGx, despite 50.2% reporting prior PGx education or training. Most providers, apart from psychiatry, perceived PGx to be at least moderately useful to inform clinical decisions. However, only 26.4% of providers had recent PGx testing experience. Unfamiliarity with PGx and uncertainty about the clinical value of testing were common perceived challenges. Conclusion: Low PGx familiarity among pediatric providers suggests additional education and electronic resources are needed for PGx examples in which data support testing in children.

Keywords: children; pediatric; perspective; pharmacogenetic; pharmacogenomic; provider; testing.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Health Knowledge, Attitudes, Practice
  • Health Personnel / economics
  • Health Personnel / standards*
  • Humans
  • Pediatrics / economics
  • Pediatrics / standards*
  • Pharmacogenetics / economics
  • Pharmacogenetics / trends
  • Pharmacogenomic Testing / economics
  • Pharmacogenomic Testing / standards*
  • Precision Medicine / trends